Qomel (9600) Fundamentals 2026 — P/E 24.9x, Revenue Analysis | SniperIQ
Qomel (9600) is a SA-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of SAR 329M, trading at SAR 47.00 on the SAU. This SniperIQ fundamentals page covers Qomel's valuation (P/E 24.9x, P/B 2.7x), profitability (net margin 11.3%), revenue (SAR 132M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Qomel's market cap?
Qomel (9600) has a market capitalization of approximately SAR 329M, trading at SAR 47.00 on the SAU. Market cap moves with the live share price.
What is Qomel's P/E ratio?
Qomel's trailing twelve-month P/E ratio is 24.9x, with a price-to-book (P/B) of 2.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Qomel?
Qomel runs a net profit margin of 11.3%, a gross margin of 30.0%, and an operating margin of 15.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Qomel generate?
Qomel reported revenue of SAR 132M for fiscal year 2025, with net income of SAR 15M and earnings per share (EPS) of 2.14. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Qomel pay a dividend?
Qomel does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Qomel financially healthy?
Qomel carries a debt-to-equity ratio of 0.32x and a current ratio of 2.31x, with a market beta of 0.52. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Qomel a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Qomel (9600) the key facts are: market cap SAR 329M, P/E 24.9x, revenue SAR 132M, 52-week range 42-59.95. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Qomel's full fundamentals live
Get Qomel's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.